Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including...
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Halle (Saale) / Munich, Germany, April 16, 2024 - Vivoryon Therapeutics N.V. (Euronext...
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
Vivoryon Alzheimer’s drug fails phase 2 trial, crashing stock
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 Halle (Saale) / Munich, Germany, January 8, 2024 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 Halle (Saale) / Munich, Germany, November 28, 2023 - Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference Halle (Saale) / Munich, Germany, November 7, 2023 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision Both VIVIAD and VIVA-MIND...
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer™s Disease to Proceed...
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders Multiple KOLs highlight varoglutamstat pathology, clinical development and clinical applicability of...